RecruitingMigraine

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

Eligible age

18–70 yrs

Accepts

All genders

Locations

22 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during research visits.

Sponsor: Mayo Clinic

You may qualify if…

✓ Adults, 18-70 years of age at the time of enrollment
✓ Migraine with aura, migraine without aura, and/or chronic migraine; according to ICHD-3 diagnostic criteria. (Those with daily or continuous headaches are not excluded.)
✓ Migraine onset prior to 50 years of age
✓ Migraine present for at least 12 months at the time of enrollment
✓ At least four "moderate to severe headache days" per month (by patient self-report and then confirmed during four-week pre-randomization headache diary phase) A "moderate to severe headache day" is defined as a day during which there is a headache of moderate to severe intensity that lasts for at least four hours, or a day on which a migraine-specific acute medication is taken to treat headache.
✓ If already taking a migraine preventive treatment, willing to continue with that treatment without dose change during the first 16 weeks of the study, including the 4-week run-in phase and 12-week randomized phase.
✓ Not pregnant or breastfeeding
✓ Women of childbearing potential must agree to use effective methods of contraception to reduce the risk of pregnancy.